LONDON--(BUSINESS WIRE)--Technavio has announced its latest pipeline analysis report on the Diarrhea market. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat chondrosarcoma.
This report by Technavio presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the coming years.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Diarrhea: Market overview
Diarrhea is a condition in which there are frequent, loose, and watery bowel movements. It usually lasts for a few days and can cause dehydration because of the fluid loss. Diarrhea can be acute and chronic. Acute diarrhea refers to the diarrhea that lasts for a short span of time and is a common problem. It usually lasts for about one or two days, but it may last longer. Chronic diarrhea lasts for a longer duration of time, and it is serious.
According to a senior analyst at Technavio for infectious and rare diseases, “Most cases of diarrhea are caused by the infection in the gastrointestinal tract. Diarrhea generally happens due to a host of bacterial, viral, and parasitic organisms, most of which are spread by feces-contaminated water. The infection is more common when there is a shortage of adequate sanitation and hygiene and safe water for drinking, cooking, and cleaning. Rotavirus and Escherichia coli are the two most common etiological agents of diarrhea.”
Diarrhea: Segmentation analysis
This market research report segments the Diarrhea market based on therapies employed including monotherapy, RoA (oral, subcutaneous, intramuscular, intranasal, rectum, and unknown), therapeutic modality (small molecule, vaccine, enzyme, peptide, biological, and monoclonal antibody, oligomer, and unknown), targets (beta-lactamase, somatostatin receptor, farnesoid X receptor, bombesin BB2 receptor, CFTR, others, and unknown), MoA (immunostimulant, somatostatin receptor agonist, bacterial growth inhibitor, bacterial protein synthesis inhibitor, bile acid binding protein modulator, others, and unknown), and recruitment status (recruiting, completed, and undisclosed).
Monotherapy includes the use of a single drug to treat a disorder or a disease. In the current pipeline, all the molecules that are being investigated for the treatment of diarrhea are monotherapy.
In case of oral RoA, the delivery of the drug substances is done through the mouth cavity. About 63% of the total molecules that are in the current pipeline are expected to be administered orally.
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Drug Development Landscape
- Drugs under development
- Indications coverage
Drug Development Strategies
- Therapies employed
- Therapeutic modality
- Geographical coverage
- Recruitment status
- Recruitment volume
- Type of players
- Company Overview
Discontinued or Dormant Molecules
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at firstname.lastname@example.org.